Clinical Trial

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

Suspended Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Drug Supply Issues
Summary
This phase I trial tests the safety, side effects and best dose of lintuzumab-Ac225 for the treatment of patients with high risk myelodysplastic syndrome that has not responded to previous treatment (refractory). Lintuzumab-Ac225 is a monoclonal antibody, called lintuzumab, linked to a radioactive agent called Ac225. Lintuzumab attaches to CD33 positive cancer cells in a targeted way and delivers Ac225 to kill them. Giving lintuzumab-Ac225 may be safe, tolerable and/or effective in treating patients with high risk, refractory myelodysplastic syndrome.
Protocol Amendment History 91 amendments
This ClinicalTrials.gov record has been amended 91 times since 2025-03-20; most recent amendment 2026-06-23.
Status change: Recruiting → Suspended 2025-10-21
Status change: Not Yet Recruiting → Recruiting 2025-08-16
Trial Details
NCT Number NCT06888323
Lead Sponsor National Cancer Institute (NCI)
Conditions Refractory Myelodysplastic Syndrome
Enrollment 18 participants
Start Date 2026-09-03
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-24